Some COVID-19 Patients Want Ivermectin So Badly They’re

New Post Public Reply Private Reply Replies (0) Message Board
Bhawks
224
Some COVID-19 Patients Want Ivermectin So Badly They’re Taking Hospitals To Court

SEP. 27, 2021, AT 6:00 AM



https://fivethirtyeight.com/features/some-cov...-to-court/

When the suburban Chicago hospital where her mother was being treated for COVID-19 refused to give her ivermectin, Tiffany Wilson had her moved to another hospital. The antiparasitic drug achieved a cult following as a treatment for COVID-19, despite no current evidence it is effective.

But that didn’t deter Wilson from suing when the next hospital also refused to give her mother, 68-year-old Leslie Pai, ivermectin. And she won. This week, after the hospital obliged a judge’s injunction ordering it to give Pai ivermectin, Pai’s heart rate plummeted, hospital doctors said in court documents. The hospital pushed back in court, and Wilson dropped the case, with her lawyers asking the court to lift the injunction while continuing to argue that the ivermectin was, in fact, helping.

The fixation on ivermectin is largely driven by online misinformation and a misrepresentation of what we know about the drug.

Ivermectin is an antiparasitic that has been around for decades and is very effective at treating certain parasitic infections, like river blindness. Its effectiveness on viral infections, particularly COVID-19, is still being investigated.

Unfortunately, there’s not yet good evidence showing it’s effective in this case, and one of the biggest papers suggesting it could be effective was withdrawn due to ethical conflicts.

That said, it’s not as if ivermectin has been written off; clinical trials to test ivermectin’s effectiveness against COVID-19 are ongoing, and their results will be carefully monitored by federal agencies and professional groups that help create guidelines for treatment.

That same process has led to other existing drugs, like the antiviral remdesivir, getting approval from the Food and Drug Administration for treating COVID-19. But neither the FDA nor the World Health Organization nor the National Institutes of Health currently approve of ivermectin for treating COVID-19.

But misinformation has convinced many people that they know more about how to treat COVID-19 than the medical establishment and experts. The thing is, they don’t. “The number of studies and the quality of them and the different research methodologies in any field of medicine is always pretty overwhelming. That’s why we have professional societies and regulatory bodies who take all of that evidence into consideration,” said Carolyn Bramante, a professor of medicine at the University of Minnesota and the principal investigator on an ongoing randomized clinical trial of ivermectin and other potential COVID-19 treatments.

It can, of course, be a good thing for patients to advocate for their own care. The difference in ivermectin cases is that their advocacy is based on rumors and lies, not on scientific evidence.

Though ivermectin has been around for decades, it’s still a drug and it can have side effects and potentially negative impacts, Bramante said. Not only is there not yet evidence that it works, we also don’t know if it could be harmful. That can also cause complications for a hospital system already stretched thin by the pandemic it’s trying to treat.

“You don’t get treated based upon what you feel or think,” Hood said. “There are certain approved treatment regimens for certain diseases. If [what a patient is demanding] doesn’t fit within that regimen, then you cannot treat them.”

Online, however, proponents of ivermectin tout it as both a prophylaxis and a cure for COVID-19, cherry-picking data from preprint studies and sharing anecdotes of miraculous recoveries. It’s an infectious narrative that leads many people to believe the drug ought to be used widely — and to wonder if the fact that it isn’t is evidence of a conspiracy. Amid the desperate haze of the pandemic, this type of thinking is leading people to extreme actions.

All this while another preventive medical intervention, one that has been shown to be highly effective and safe — the vaccine — is shunned by many of the same people. These lawsuits may represent a precedent of conspiracy-theory-influenced patients using the courts as a cudgel to force medical professionals to practice against their own expertise. Right now, it’s ivermectin, but what’s stopping patients from demanding to be treated with colloidal silver or bleach?

Kaleigh Rogers is FiveThirtyEight’s technology and politics reporter.

Andy Freeland

Brett Bellmore Yeah, who needs them fancified "doctors" to write "prescriptions"? Let these folks prescribe themselves any ol' loony treatment for themselves and their children - antifreeze, rattlesnake bites, bats' gizzards, eye of newt - since they really know more'n them educated elite! It's the Brave New tRu*mpy World!

Wayne Insko

Been following a Facebook posting all weekend on mRNA vaccines from University Hospital's. The dis/misinformation, right-wing propaganda and lack of even high school level understanding or misrepresentation of even basic vaccination science has been staggering. The consistency of the frightwing position in re whether Ivermictin should be accepted treatment falls totally in line with this article
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 3

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 3

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading

Top 5 Most Recently Viewed Articles

OPENLANE's Strategic Repurchase Enhances Shareholder Value

Updated Category News Views 163

OPENLANE Strengthens Position with Series A Stock Repurchase OPENLANE, Inc. (NYSE: KAR) has announced a significant development in its corporate strategy by successfully repurchasing 53% of its Series A Convertible Preferred Stock. This strategic move underscores OPENLANE's robust market presence as a dominant operator in digital marketplaces for wholesale used vehicles....

Continue Reading
Wingstop Faces Challenges Amid Shifting Consumer Preferences

Updated Category News Views 340

Wingstop's Recent Financial Performance Overview Wingstop Inc. (NASDAQ: WING) shares saw a noticeable surge following the release of their latest financial results. Although the company reported earnings of $1.09 per share, which is an improvement from $0.89 the previous year, overall revenue did not meet Wall Street expectations. The reported total revenue of $175.74...

Continue Reading
XPO Recognized as a Top Reliable Company for 2025 by Newsweek

Updated Category News Views 47

XPO Shines as One of America’s Most Reliable Companies XPO (NYSE: XPO), recognized as a premier provider of freight transportation in North America, has recently been named one of the prestigious 'Most Reliable Companies' for 2025 by Newsweek magazine. This accolade is part of Newsweek's inaugural list that celebrates U.S.-based companies noted for their unwavering...

Continue Reading
Man Group PLC Details Declarations for Market Investors

Updated Category News Views 113

Important Information Regarding Man Group PLC's Position Man Group PLC has recently provided an overview of its investment interests and positions in American Axle & Manufacturing Holdings Inc. This disclosure is crucial for shareholders and potential investors looking to understand the company's current market stance. Key Disclosures from Man Group PLC Under Rule 8.3 of...

Continue Reading
Flex Ltd. Schedules Quarterly Results Financial Call

Updated Category News Views 190

Flex Ltd. Sets Date for Upcoming Earnings Call Flex (NASDAQ: FLEX) has recently announced an important date for shareholders and stakeholders to mark on their calendars. The company will unveil its financial results for the fourth quarter and fiscal 2025 before the market opens on a Wednesday in May. This event is eagerly anticipated as it provides insights into Flex’s...

Continue Reading